For research and educational purposes only. Not medical advice.
Semax Reference
Educational, not medical advice reference for Semax: Cognitive; regulatory status, evidence posture, source review, and schedule notes. Also known as Semax h…
Reference summary
Most accessible peer-reviewed evidence is preclinical, largely in rodent ischemia and neurotrophin-expression models. English-language human evidence remains limited despite reports of Russian clinical use.
- Categories
- Cognitive
- Aliases
- Semax heptapeptide, ACTH(4-7) Pro-Gly-Pro analog
- Evidence posture
- translational — Accessible evidence is mostly preclinical or older non-US literature.
- Regulatory status
- No FDA-approved Semax drug label. Semax is registered in Russia for neurological indications and is listed among bulk substances with safety-risk concerns by FDA.
- Content review status
- research reference